Anna Tate Riegel

Title

Professor
Professor of Oncology and Pharmacology

Department

Breast Cancer

General profile
Research
Publications

Publications

Articles in journals

Oh,AS, Lahusen,JT, Chien,CD, Fereshteh,MP,Zhaang X, Dakshanamurthy,S, Xu,J, Kagan,BL, Wellstein,A and Riegel AT.. " Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.." Molecular and Cellular Biology 28 (2008): 6580-6593.
Fereshteh MP, Tilli MT, Kim S, Xu J, O’Malley BW , Wellstein A, Furth PA, and Riegel AT. . "The nuclear receptor coactivator AIB1/SRC-3 is required for Neu (ErbB2/HER2) activation, signaling and mammary tumorigenesis in mice.." Cancer Research 68.10 (2008): 3697-1706.
LahusenT., Fereshteh M., Oh A., Wellstein A. and Riegel, AT. "EGFR tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator AIB1. ." Cancer Research 65.15 (2007): 7256-7265.
Kuo AH., Stoica GE., Riegel AT. and Wellstein A. "Recruitment of Insulin Receptor Substrate-1 and Activation of NF-kB Essential for Midkine Growth Signaling Through Anaplastic Lymphoma Kinase. ." Oncogene 25 (2007): 859-869.
Mani A., Oh AS., Bowden ET., Lahusen T., Lorick KL., Weissman AM., Schelgel R., Wellstein A. and Riegel AT. "E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator AIB1/SRC-3 in immortalized cells ." Cancer Research 66.17 (2006): 8680-8686.
Briones VR., Chen S., Riegel AT. and Lechleider RJ. "Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta. ." Biochem Biophys Res Commun. 345.2 (2006): 595-601.
Xie B., Tassi E., Swift MR., McDonnell K., Bowden ET., Wang S., Ueda Y., Tomita Y., Riegel AT., Wellstein A. "Identification of the Fibroblast Growth Factor (FGF)-interacting Domain in a Secreted FGF-binding Protein by Phage Display. ." J Biol Chem. 2006 Jan 13;281(2):1137-44. 281.2 (2006): 1137-1134.
Tilli MT., Reiter R., Oh AS., Henke RT., McDonnell K., Gallicano GI., Furth P. and Riegel AT. "Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator AIB1/ACTR leads to altered proliferation of mammary epithelial cells in transgenic mice." Molecular Endocrinology (2005) 19: 644-656 19 (2005): 644-656.
McDonnell K., Bowden ET., Cabal-Manzano R., Hoxter B., Riegel AT. and Wellstein A. "Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. ." Molecular Endocrinology 19 (2005): 644-656.
Malerczyk C, Schulte AM, Czubayko F, Bellon L, Macejak D, Riegel AT and Wellstein A. "Ribozyme targeting of the growth factor pleiotrophin in established tumors, a gene therapy approach. ." Gene Therapy 12 (2005): 339-346.
Malerczyk C., Schulte AM., Czubayko F., BellonL., Macejak D., Riegel AT. and Wellstein A.. "Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene targeting approach. ." Gene Therapy 12.4 (2005): 339-346.
Oh A., ListH-J., ReiterR., Mani A., Zhang Y., Gehan E., Wellstein A. and Riegel AT. "The nuclear receptor coactivator AIB1 mediates IGF-1 induced phenotypic changes in human breast cancer cells. ." Cancer Research 64 (2004): 8299-9308.
Henke RT., Haddad BR., Kim SE., Rone JD., Mani A., Jessup JM., Wellstein A. Maitra A. and Riegel AT. "Overexpression of the nuclear receptor coactivator AIB1(SRC-3) during progression of pancreatic adenocarcinoma. ." Clinical Cancer Research 2004 10, 6134-6142 10 (2004): 6134-6142.
Reiter R., Oh AS., Wellstein A. and Riegel AT. "Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. ." Oncogene. 2004 23, 403-409 23 (2004): 403-409.
Ray R., Cabal-Manzano R., Moser AR., Waldman T., Zipper LM., Aigner A., Byers SW., Riegel AT. and Wellstein A. "Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis.." Cancer Res. 63.23 (2003): 8085-8089.
Kagan BL., Henke RT., Cabal-Manzano R., Stoica GE., Nguyen Q., Wellstein A. and Riegel AT. "Complex regulation of the fibroblast growth factor binding protein (FGF-BP) in MDA MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. ." Cancer Res 63 (2003): 1696-1705.
Lauritsen K., List H-J., Reiter R., Wellstein A. and Riegel AT. "A role for TGF-? in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. ." Oncogene. 2002 Oct 17;21(47):7147-55. 21.47 (2002): 7147-7155.
Stoica GE., Kuo A., Powers C., Bowden ET., Buchert Sale E., Riegel AT. and Wellstein A. "Midkine binds to Anaplastic Lymphoma Kinase (ALK) and acts as a growth factor for different cell types. ." J Biol Chem 277, 35990-35998, 2002. 277 (2002): 35990-35998.
Reiter R., Wellstein A. and Riegel AT. "An isoform of the coactivator AIB1, that increases hormone and growth factor sensitivity, is overexpressed in breast cancer. ." J Biol Chem 276 (2001): 39736-39741.
List H-J., Lauritsen K., Reiter R., Powers C., Wellstein, A. and Riegel AT. "Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate limiting factor for estrogen dependent growth of human MCF-7 breast cancer cells. ." J Biol Chem . 276 (2001): 23763-23768.
List H-J., Reiter R., Singh B., Wellstein A. and Riegel, A.T. "Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. ." Breast Canc Res Treatment 68.1 (2001): 1-8.
Harris VK., Kagan BL., Ray R., Coticchia CM., Liaudet-Coopman EDE., Wellstein A. and Riegel AT. "Serum induction of the fibroblast growth factor binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP regulated transcription. ." Oncogene 20 (2001): 1730-1738.
Stoica GE., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., Caughey DJ., Wen D., Karavanov A., Riegel AT. and Wellstein A. "Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin ." J Biol Chem 276, 16772-16779, 2001. 276 (2001): 16772-16779.
Reiter R., Wellstein A. and Riegel AT. "An isoform of the coactivator AIB1, that increases hormone and growth factor sensitivity, is overexpressed in breast cancer. ." J Biol Chem 276 (2001): 39736-39741.
List H-J., Smith CL., Martinez E., Harris VK., Danielsen M., and Riegel AT. "Effects of Anti-androgens on chromatin remodeling and transcription of the integrated mouse mammarty tumor virus promoter." Exp Cell Res 260, 160-165 2000. 260 (2000): 160-165.
Boyle B., Harris VK., Liaudet-Coopman EDE., Riegel AT. and Wellstein A. "Differential regulation of gene expression of a binding protein for Fibroblast Growth Factors by RAR and RXR –selective analogs of retinoic acid." Biochem Pharm 60, 1677-1684 2000. 60 (2000): 1677-1684.
Harris VK., Coticchia CM. List H-J., Wellstein A. and Riegel AT. "Mitogen-induced expression of FGF-BP binding protein is transcriptionally repressed through a non-canonical E-Box element. ." J Biol Chem 275 (2000): 28539-28548.
Harris VK., Cottichia CM., Kagan BL., Wellstein A. and Riegel AT. "Induction of the angiogenic modulator FGF-BP by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways." J Biol Chem 275, 10802-10811, 2000. 275 (2000): 10802-10811.
Schulte AM., Malerczyk C., Cabal-Manzano R., Gajarsa J., List H-J., Riegel AT. and Wellstein A. "Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of the growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site. ." Oncogene 19, 3988-3998 2000 19 (2000): 3988-3998.